Etravirine (TMC125)

• CAT Number: A000606
• CAS Number: 269055-15-4
• Molecular Formula: C20H15BrN6O
• Molecular Weight: 435.3
• Purity: ≥95%
• Target: HIV
• Solubility: >19.4mg/mL in DMSO
• Storage: 3 years -20C powder
• InChIKey: PYGWGZALEOIKDF-UHFFFAOYSA-N

Etravirine, also known as TMC 125 and R 165335, is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It was also approved in 2008. Etravirine, in combination with other anti-retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.

Reference

1: Nelson M, Hill A, van Delft Y, Moecklinghoff C. Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. AIDS Res Treat. 2014;2014:636584. doi: 10.1155/2014/636584. Epub 2014 Feb 25. Review. PubMed PMID: 24715982; PubMed Central PMCID: PMC3955667.2: Casado JL. Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. AIDS Rev. 2013 Jul-Sep;15(3):139-45. Review. PubMed PMID: 24002197.3: Schrijvers R. Etravirine for the treatment of HIV/AIDS. Expert Opin Pharmacother. 2013 Jun;14(8):1087-96. doi: 10.1517/14656566.2013.787411. Epub 2013 Apr 8. Review. PubMed PMID: 23560740.4: McNicholl IR. Does once-daily etravirine have a role in the management of HIV-1 infection? Drugs. 2013 Mar;73(3):207-12. doi: 10.1007/s40265-013-0022-6. Review. PubMed PMID: 23420097.5: Croxtall JD. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Drugs. 2012 Apr 16;72(6):847-69. doi: 10.2165/11209110-000000000-00000. Review. PubMed PMID: 22512366.6: Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39. doi: 10.2165/11534740-000000000-00000. Review. PubMed PMID: 21142266.7: Dickinson L, Khoo S, Back D. Pharmacokinetic evaluation of etravirine. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1575-85. doi: 10.1517/17425255.2010.535811. Review. PubMed PMID: 21077784.8: Fullerton DS, Watson MJ, Anderson D, Witek J, Martin SC, Mrus JM. Pharmacoeconomics of etravirine. Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):485-95. doi: 10.1586/erp.10.55. Review. PubMed PMID: 20950062.9: Yeni P, Mills A, Peeters M, Vingerhoets J, Kakuda TN, De Smedt G, Woodfall B. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals. Curr HIV Res. 2010 Oct;8(7):564-76. Review. PubMed PMID: 20946097.10: Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther. 2010;15(6):817-29. doi: 10.3851/IMP1652. Review. PubMed PMID: 20834094.11: Towner WJ, Cassetti I, Domingo P, Nijs S, Kakuda TN, Vingerhoets J, Woodfall B. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010;15(6):803-16. doi: 10.3851/IMP1651. Review. PubMed PMID: 20834093.12: Grinsztejn B, Di Perri G, Towner W, Woodfall B, De Smedt G, Peeters M. A review of the safety and tolerability profile of the next-generation NNRTI etravirine. AIDS Res Hum Retroviruses. 2010 Jul;26(7):725-33. doi: 10.1089/aid.2009.0293. Review. PubMed PMID: 20624073.13: Martínez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Rev. 2010 Jan-Mar;12(1):52-9. Review. PubMed PMID: 20216910.14: Domingo P. [Role of etravirine in combination antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:46-51. doi: 10.1016/S0213-005X(09)73219-7. Review. Spanish. PubMed PMID: 20116628.15: Santos Gil Ide L. [Etravirine in special populations]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:40-5. doi: 10.1016/S0213-005X(09)73218-5. Review. Spanish. PubMed PMID: 20116627.16: Llibre JM, Santos JR, Clotet B. [Etravirine: genetic barrier and resistance development]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:32-9. doi: 10.1016/S0213-005X(09)73217-3. Review. Spanish. PubMed PMID: 20116626.17: Pérez VE, Sánchez-Parra C, Serrano Villar S. [Etravirine drug interactions]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:27-31. doi: 10.1016/S0213-005X(09)73216-1. Review. Spanish. PubMed PMID: 20116625.18: Portilla J. [Safety and tolerability of etravirine]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:21-6. doi: 10.1016/S0213-005X(09)73215-X. Review. Spanish. PubMed PMID: 20116624.19: Garcés PA, Tena EV. [Etravirine in first-line therapy]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:12-20. doi: 10.1016/S0213-005X(09)73214-8. Review. Spanish. PubMed PMID: 20116623.20: Palter DP, Corbera EF, Tiraboschi JM. [Etravirine in highly treatment-experienced patients]. Enferm Infecc Microbiol Clin. 2009 Dec;27 Suppl 2:6-11. doi: 10.1016/S0213-005X(09)73213-6. Review. Spanish. PubMed PMID: 20116622.